Humana (HUM) Expected to Post Quarterly Earnings on Wednesday

Humana (NYSE:HUM) is anticipated to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $7.25 per share and revenue of $40.5673 billion for the quarter. Humana has set its FY 2026 guidance at 9.000- EPS. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. During the same period in the previous year, the firm posted $11.58 earnings per share. The business’s revenue was up 23.5% on a year-over-year basis. On average, analysts expect Humana to post $9 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Humana Stock Performance

Shares of HUM stock opened at $404.80 on Wednesday. Humana has a 12-month low of $163.11 and a 12-month high of $428.88. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market capitalization of $48.60 billion, a price-to-earnings ratio of 43.29, a price-to-earnings-growth ratio of 2.17 and a beta of 0.71. The business has a 50 day simple moving average of $358.69 and a 200 day simple moving average of $262.23.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. Morgan Stanley boosted their price target on Humana from $217.00 to $249.00 and gave the stock an “underweight” rating in a research report on Thursday, June 4th. William Blair began coverage on Humana in a report on Wednesday, May 20th. They set an “outperform” rating on the stock. Oppenheimer upgraded shares of Humana from an “outperform” rating to an “outperform” rating in a research note on Wednesday, May 20th. UBS Group reaffirmed a “neutral” rating on shares of Humana in a report on Monday, June 15th. Finally, The Goldman Sachs Group increased their target price on shares of Humana from $158.00 to $195.00 and gave the company a “sell” rating in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $327.17.

Institutional Trading of Humana

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in Humana by 1.8% in the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock worth $1,403,877,000 after buying an additional 97,211 shares during the last quarter. Invesco Ltd. lifted its position in shares of Humana by 9.3% during the 4th quarter. Invesco Ltd. now owns 2,233,130 shares of the insurance provider’s stock valued at $571,972,000 after acquiring an additional 189,670 shares during the last quarter. Naya Capital Management UK Ltd. lifted its position in shares of Humana by 59.1% during the 4th quarter. Naya Capital Management UK Ltd. now owns 1,243,184 shares of the insurance provider’s stock valued at $318,417,000 after acquiring an additional 461,563 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Humana by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,207,759 shares of the insurance provider’s stock valued at $309,343,000 after acquiring an additional 50,403 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Humana by 4,481.7% during the 4th quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider’s stock worth $306,460,000 after acquiring an additional 1,170,387 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.